Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity.

"data availability raw exome sequencing and rna-seq data from bortolomeazzi et al 50 are available through controlled-access application via the european genome-phenome archive (hosted by the embl-ebi and the crg) under accession no egad00001006165 .; the sequencing data generated in the present study are available at ena under primary accession no prjeb56609 .; raw ms data generated in the present study are available at massive under accession no msv000092096 . code availability customized scripts used in the analysis of sequencing data in the present study are available at: https://github com/cortes-ciriano-lab/mmrd_immunogenicity ."

"code availability customized scripts used in the analysis of sequencing data in the present study are available at: https://github com/cortes-ciriano-lab/mmrd_immunogenicity ."

"Competing interests T.J. is a member of the Board of Directors of Amgen and Thermo Fisher Scientific, and a co-founder of Dragonfly Therapeutics and T2 Biosystems. He serves on the Scientific Advisory Board of Dragonfly Therapeutics, SQZ Biotech and Skyhawk Therapeutics, and is the President of Break Through Cancer. None of these affiliations represents a conflict of interest with respect to the design or execution of the present study or interpretation of data presented in this manuscript. The Jacks laboratory also currently receives funding from the Johnson & Johnson Lung Cancer Initiative and the Lustgarten Foundation for Pancreatic Cancer Research, but this did not support the research described in the present study. All other authors declare no competing interests."

"FundingInformation Open access funding provided by European Molecular Biology Laboratory (EMBL)."